Evidence map›Paper›PMID 39171923›Full record

ArticlemSphere2024

Valerio Capitani, Gabriele Arcari, Cecilia Ambrosi, Daniela Scribano, Mariateresa Ceparano, Riccardo Polani, Alice De Francesco, Giammarco Raponi, Giancarlo Ceccarelli, Paolo Villari and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in mSphere, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Hypermucoviscosity inJournal of bacteriology · 2026
    Review
  2. Article
  3. Article
  4. The acquisition ofmBio · 2026
    Article
  5. Article
  6. The acquisition ofbioRxiv : the preprint server for biology · 2025
    Article
  7. Review
  8. Infection and immunity · 2025
    Review
  9. HypervirulentPathogens & immunity · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Valerio Capitani *Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.ORCID 0009-0008-4569-1972
Gabriele Arcari *Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy.
Cecilia AmbrosiDepartment of Promotion of Human Sciences and Quality of Life, San Raffaele University, Rome, Italy.ORCID 0000-0003-2163-1613
Daniela ScribanoDepartment of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.ORCID 0000-0002-2901-265X
Mariateresa CeparanoDepartment of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.
Riccardo PolaniDepartment of Molecular Medicine, Sapienza University of Rome, Rome, Italy.
Alice De FrancescoDepartment of Molecular Medicine, Sapienza University of Rome, Rome, Italy.
Giammarco RaponiDepartment of Molecular Medicine, Sapienza University of Rome, Rome, Italy.
Giancarlo CeccarelliDepartment of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.
Paolo VillariDepartment of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.
Anna Teresa PalamaraDepartment of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy.
Carolina MarzuilloDepartment of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.
Alessandra CarattoliDepartment of Molecular Medicine, Sapienza University of Rome, Rome, Italy.ORCID 0000-0002-6120-6526

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Carbapenemase-producing IMPORTANCE: Here we describe the evolution of KPC-3-producing ST512

Indexed as

Anti-Bacterial AgentsAzabicyclo CompoundsCeftazidimeDrug CombinationsKlebsiella InfectionsKlebsiella pneumoniaeLiver AbscessMicrobial Sensitivity TestsBacterial Proteinsbeta-LactamasesBiofilmsDrug Resistance, Multiple, BacterialEvolution, MolecularHumansPolymorphism, Single NucleotideVirulenceAnti-Bacterial Agentsavibactam, ceftazidime drug combinationAzabicyclo CompoundsBacterial Proteinsbeta-LactamasesCeftazidimeDrug Combinationsantibiotic resistancecapsulehmvhypermucoidhypervirulenceKPC-31mucoviscousrmpA negativeserum susceptibilityST512string testwzc

Identifiers

PMID39171923
PMCPMC11423586

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.